成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

美國LightLab imaging 
LightLab imaging 公司是一家以光學干涉斷層成像系統（OCT）等血管內超聲產品研發為主的國際性公司,于1998年2月成立,總部在美國。Lightlab公司擁有具備國際領先水平、實力雄厚的科技研發團隊,其員工主要來自于麻省理工學院（MIT）、哈佛大學（Harvard）、林肯（Lincoln）實驗室、卡爾.蔡司（Carl Zeiss ）公司、惠普（HP）公司，安捷倫科技公司（Agilent），波士頓科學公司（BSC）和巴德公司（Bard），他們不僅具有豐富的醫療和器械行業經驗，而且是OCT研發和應用領域的專家。

OCT是一種新的高分辨率高速血管內成像方式，它綜合了先進的光學技術、超敏感探測和計算機圖像處理技術，可快速獲得血管內結構的斷層圖像。同時作為“體內的組織學顯微鏡”，OCT成像系統已經成為評價不穩定斑塊和支架治療效果的理想手段。其知識產權來自于麻省理工學院（MIT）, 哈佛大學（Harvard University）, 馬薩諸塞州總醫院（Massachusetts General Hospital）, 塔夫茨大學（Tufts University）, 美敦力（Medtronic）及蔡司基金會（the Zeiss Foundation）。

OCT產品一直受到全世界臨床醫學研究工作者的關注，在近年來的國際科學和醫學會議中也備受矚目。LightLab Imaging公司為OCT產品制定了全球化的發展戰略。公司秉承的使命是：為冠心病早期診斷及介入治療提供更早、更精準的臨床診斷數據。

LightLab Imaging is focused on developing Optical Coherence Tomography (OCT). OCT is a new high-resolution high-speed imaging modality that uses advanced photonics for imaging and tissue characterization. Our mission is to help physicians make earlier and more accurate diagnosis of a wide range of diseases including heart disease and cancer.

OCT has been the subject of intensive, worldwide research efforts and is featured prominently at international scientific and medical conferences. LightLab has developed a strong portfolio of fundamental OCT patents.

LightLab Imaging was founded in February of 1998. The President and CEO is David Kolstad.

LightLab employees include pioneers in the development and application of OCT from MIT, Harvard, Lincoln Laboratory and Carl Zeiss, Inc. Company executives and staff also contribute a strong knowledge of heath care and medical device development with significant experience in device development, manufacturing and marketing with companies such as Hewlett-Packard, Agilent Technologies, Boston Scientific and C.R. Bard.

LightLab Imaging has a strong intellectual property position with technology acquired from MIT, Harvard University, Massachusetts General Hospital, Tufts University, Medtronic, and the Zeiss Foundation, as well as numerous internally developed patents.